Matches in SemOpenAlex for { <https://semopenalex.org/work/W4254687550> ?p ?o ?g. }
Showing items 1 to 61 of
61
with 100 items per page.
- W4254687550 endingPage "8551" @default.
- W4254687550 startingPage "8551" @default.
- W4254687550 abstract "8551 Background: Female survivors of chest radiation (RT) for HD have an increased risk of breast cancer (BC) that develops at a relatively young age, often prior to menopause. Tamoxifen has not been studied in the prevention of radiogenic BC. In order to design a randomized BC prevention trial of tamoxifen for this cohort, we conducted a single-arm study, assessing enrollment, adherence, and toxicity. Methods: Eligible women were diagnosed with HD age ≤30, ≥5 years from mantle/chest RT, completed childbearing and had no history of thrombosis or second malignancy. Women were invited by letter to participate in this one-year study of tamoxifen, annual mammogram, breast exams at 6 and 12 months and other monitoring, (with the option of continuing tamoxifen for 5 years). In addition, patients could be referred by their MD. Results: Of 272 women identified, 67 were lost to follow-up and 14 were ineligible for medical reasons. Of the remaining 191 women, 164 (86%) declined. Reasons were “fear of side effects” (27%); “not completed childbearing”(18%); “too busy” (9%); “do not want to take medication” (8%); “MD advised against” (4%) and other (34%). Twenty-nine women (median age 41, range 34–55; median time since HD 19 years, range 6–36) enrolled on the study and began therapy. Median time of tamoxifen exposure is 18 months (range 2–24 months). Nine women (31%) discontinued tamoxifen prior to completing a full year of treatment. Reasons were side effects (4), other medical problems (2), BC (1), and other (2). There were no unusual or serious side effects. Conclusions: Despite their increased BC risk and tamoxifen's efficacy in other populations, female HD survivors were not eager to take tamoxifen. Because the risk of early onset BC is substantial in HD survivors, other prevention strategies, including novel agents should be considered. No significant financial relationships to disclose." @default.
- W4254687550 created "2022-05-12" @default.
- W4254687550 creator A5013719754 @default.
- W4254687550 creator A5016016418 @default.
- W4254687550 creator A5017730360 @default.
- W4254687550 creator A5021488317 @default.
- W4254687550 creator A5026555041 @default.
- W4254687550 creator A5054592331 @default.
- W4254687550 creator A5059060486 @default.
- W4254687550 date "2004-07-15" @default.
- W4254687550 modified "2023-10-17" @default.
- W4254687550 title "A feasibility study of tamoxifen chemoprevention in Hodgkin's disease (HD) survivors" @default.
- W4254687550 doi "https://doi.org/10.1200/jco.2004.22.14_suppl.8551" @default.
- W4254687550 hasPublicationYear "2004" @default.
- W4254687550 type Work @default.
- W4254687550 citedByCount "1" @default.
- W4254687550 countsByYear W42546875502015 @default.
- W4254687550 crossrefType "journal-article" @default.
- W4254687550 hasAuthorship W4254687550A5013719754 @default.
- W4254687550 hasAuthorship W4254687550A5016016418 @default.
- W4254687550 hasAuthorship W4254687550A5017730360 @default.
- W4254687550 hasAuthorship W4254687550A5021488317 @default.
- W4254687550 hasAuthorship W4254687550A5026555041 @default.
- W4254687550 hasAuthorship W4254687550A5054592331 @default.
- W4254687550 hasAuthorship W4254687550A5059060486 @default.
- W4254687550 hasConcept C121608353 @default.
- W4254687550 hasConcept C126322002 @default.
- W4254687550 hasConcept C2777176818 @default.
- W4254687550 hasConcept C2777757722 @default.
- W4254687550 hasConcept C29456083 @default.
- W4254687550 hasConcept C530470458 @default.
- W4254687550 hasConcept C71924100 @default.
- W4254687550 hasConcept C72563966 @default.
- W4254687550 hasConceptScore W4254687550C121608353 @default.
- W4254687550 hasConceptScore W4254687550C126322002 @default.
- W4254687550 hasConceptScore W4254687550C2777176818 @default.
- W4254687550 hasConceptScore W4254687550C2777757722 @default.
- W4254687550 hasConceptScore W4254687550C29456083 @default.
- W4254687550 hasConceptScore W4254687550C530470458 @default.
- W4254687550 hasConceptScore W4254687550C71924100 @default.
- W4254687550 hasConceptScore W4254687550C72563966 @default.
- W4254687550 hasIssue "14_suppl" @default.
- W4254687550 hasLocation W42546875501 @default.
- W4254687550 hasOpenAccess W4254687550 @default.
- W4254687550 hasPrimaryLocation W42546875501 @default.
- W4254687550 hasRelatedWork W1991900845 @default.
- W4254687550 hasRelatedWork W1996337195 @default.
- W4254687550 hasRelatedWork W2009869235 @default.
- W4254687550 hasRelatedWork W2049566046 @default.
- W4254687550 hasRelatedWork W2053875111 @default.
- W4254687550 hasRelatedWork W2080631897 @default.
- W4254687550 hasRelatedWork W2349037803 @default.
- W4254687550 hasRelatedWork W2466620260 @default.
- W4254687550 hasRelatedWork W290353775 @default.
- W4254687550 hasRelatedWork W2929820373 @default.
- W4254687550 hasVolume "22" @default.
- W4254687550 isParatext "false" @default.
- W4254687550 isRetracted "false" @default.
- W4254687550 workType "article" @default.